IMRT Reirradiation with Concurrent Cetuximab Immunotherapy in Recurrent Head and Neck Cancer

摘要: In this retrospective investigation, the outcome and toxicity after reirradiation with concurrent cetuximab immunotherapy of recurrent head neck cancer (HNC) in patients who had contraindications to platinum-based chemotherapy were analyzed. Ten locally advanced HNC were retrospectively evaluated. 9 cases, histology was squamous cell carcinoma, one case adenoid cystic carcinoma. External beam radiotherapy was part of initial treatment in all cases. Reirradiation carried out using step-and-shoot intensity-modulated (IMRT) a median dose of 50.4 Gy. Cetuximab applied as loading (400 mg/m2) 1 week prior then weekly concurrently with radiotherapy (250 mg/m2). The overall survival time initiation 7 months; 1-year (OS) rate was 40%. Local failure found 3 patients, resulting local control (LC) 61%. locoregional control (LRC) 44%, while distant metastasis-free (DMFS) 75%. Acute hematological not observed in group. Severe acute included fatal infield arterial bleeding flap necrosis. late toxicities were noted 2 patients: fibrosis temporomandibular joint patient stenosis cervical esophagus another. IMRT immunotherapy is feasible acceptable acute toxicity. Further investigations are necessary determine clinical role therapy concept.